Ligand validation:6JY9

OLA: OLEIC ACID

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6JY9_OLA_A_304	44%	46%	0.121	0.902	0.95	1.15	1	2	1	0	70%	0.7
6JY9_OLA_A_305	39%	57%	0.192	0.899	0.8	0.86	1	-	1	0	100%	1
6JY9_OLA_A_311	29%	69%	0.142	0.9	0.34	0.84	-	-	0	0	45%	0.45
6JY9_OLA_A_309	29%	59%	0.144	0.892	0.98	0.62	1	-	0	0	50%	0.5
6JY9_OLA_A_308	28%	43%	0.092	0.812	1.04	1.16	1	1	0	0	60%	0.6
6JY9_OLA_A_306	23%	52%	0.146	0.787	0.83	1.01	1	2	0	0	90%	0.9
6JY9_OLA_A_310	21%	76%	0.133	0.868	0.33	0.6	-	-	1	0	30%	0.3
6JY9_OLA_A_313	15%	49%	0.151	0.806	0.73	1.24	-	1	0	0	45%	0.45
6JY9_OLA_A_312	12%	48%	0.213	0.838	0.7	1.29	-	2	0	0	45%	0.45
6JY9_OLA_A_307	9%	53%	0.176	0.753	0.66	1.14	-	-	1	0	50%	0.5
6JY9_OLA_A_314	6%	60%	0.198	0.721	0.81	0.71	1	-	0	0	55%	0.55
5G28_OLA_A_1275	49%	41%	0.083	0.927	1.15	1.14	1	1	1	0	45%	0.45
7CRL_OLA_A_305	49%	39%	0.134	0.878	1	1.39	1	2	1	0	100%	0.7582
7CRJ_OLA_A_305	48%	49%	0.13	0.87	0.9	1.05	1	2	0	0	100%	0.8453
6JYC_OLA_A_304	47%	47%	0.132	0.923	0.95	1.1	1	1	2	0	70%	0.7
6JY7_OLA_A_304	46%	46%	0.121	0.91	0.95	1.15	1	2	1	0	70%	0.7
6DJ6_OLA_B_402	92%	68%	0.081	0.971	0.55	0.69	-	-	0	0	100%	1
1LFO_OLA_A_128	79%	59%	0.097	0.943	0.78	0.79	1	-	0	0	100%	1
8GEW_OLA_A_202	64%	57%	0.138	0.938	0.69	0.94	-	2	0	0	100%	0.44
7V3K_OLA_D_401	55%	65%	0.16	0.928	0.6	0.74	-	-	2	0	100%	1
7KAZ_OLA_B_600	54%	53%	0.126	0.891	0.82	0.99	1	1	0	0	100%	0.87

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.